Unogen Biotech

Unogen Biotech is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, focused on the discovery and development of innovative recombinant protein drugs. The company utilizes its proprietary protein engineering platforms to develop long-acting cytokines and fusion proteins that enhance the body's immune response against cancer and infectious diseases. Its lead program, UNG-001, is a long-acting recombinant human Interleukin-7 (IL-7) fusion protein currently in Phase 2 clinical development for treating lymphopenia and enhancing immunotherapy efficacy. Unogen's pipeline also includes several early-stage candidates targeting other key immune pathways, such as IL-15 and IL-2. The company aims to leverage its expertise in protein half-life extension to create more effective and convenient treatments for patients with significant unmet medical needs.